

1 **A retrospective analysis of gender parity in scientific authorship in a**
2 **biomedical research centre**

3 Rinita Dam^{1*}, rinita.dam@rdm.ox.ac.uk * Corresponding author

4 Syed Ghulam Sarwar Shah^{1,2**}, Sarwar.Shah@ouh.nhs.uk * Corresponding author

5 Maria Julia Milano¹⁺, colomilano@gmail.com

6 Laurel D Edmunds¹, laureledmunds@gmail.com

7 Lorna R Henderson^{1,2}, lorna.henderson@ouh.nhs.uk

8 Catherine R Hartley³, Catherine.hartley@bodleian.ox.ac.uk

9 Owen Coxall³, owen.coxall@bodleian.ox.ac.uk

10 Pavel V Ovseiko¹, pavel.ovseiko@rdm.ox.ac.uk

11 Alastair M Buchan¹, alastair.buchan@medsci.ox.ac.uk

12 Vasiliki Kiparoglou^{2,4}, vasiliki.kiparoglou@ouh.nhs.uk

13 **Author institutional addresses**

14 ¹ Radcliffe Department of Medicine. Medical Sciences Division, University of Oxford, Oxford, United
15 Kingdom.

16 ² National Institute for Health Research Oxford Biomedical Research Centre, Oxford University
17 Hospitals NHS Foundation Trust, Oxford, United Kingdom.

18 ³ Bodleian Health Care Libraries, University of Oxford, Oxford, United Kingdom.

19 ⁴ Nuffield Department of Primary Health Care Sciences University of Oxford, Oxford.

20 +RD, SGSS and MJM contributed equally to this paper and are joint first authors on this work.

21 Word count: 4377 (excluding references)

22 ABSTRACT

23 **Objective:** Scientific authorship is a vital marker of success in academic careers and gender equity is
24 a key performance metric in research. However, there is little understanding of gender equity in
25 publications in biomedical research centres funded by the National Institute for Health Research
26 (NIHR). This study assesses the gender parity in scientific authorship of biomedical research.
27

28 **Design:** A retrospective descriptive study.

29 **Setting:** NIHR Oxford Biomedical Research Centre.

30 **Data:** 2409 publications accepted or published from 1 April 2012 to 31 March 2017.

31 **Main outcome measures:** Gender of authors, defined as a binary variable comprising either male or
32 female categories, in six authorship categories: first author, joint first authors, first corresponding
33 author, joint corresponding authors, last author and joint last authors.

34 **Results:** Publications comprised clinical research (39%, n=939), basic research (27%, n=643), and
35 other types of research (34%, n=827). The proportion of female authors as first author (41%), first
36 corresponding authors (34%) and last author (23%) was statistically significantly lower than male
37 authors in these authorship categories. Of total joint first authors (n=458), joint corresponding
38 authors (n=169), and joint last authors (n=229), female only authors comprised statistically
39 significant smaller proportions i.e. 15% (n=69), 29% (n=49) and 10% (n=23) respectively, compared
40 to male only authors in these joint authorship categories. There was a statistically significant
41 association between gender of the last author(s) with gender of the first author(s) (χ^2 33.742, $P <$
42 0.001), corresponding author(s) (χ^2 540.774, $P <$ 0.001) and joint last author(s) (χ^2 91.291, $P <$ 0.001).

43 **Conclusions:** Although there are increasing trends of female authors as first authors (41%) and last
44 authors (23%), female authors are underrepresented compared to male authors in all six categories
45 of scientific authorship in biomedical research. Further research is needed to encourage gender
46 parity in different categories of scientific authorship.

47 **Strengths and limitations of this study**

- 48 • This is the first study to investigate gender parity in six categories of scientific authorship:
49 first authors, first corresponding authors, last authors and three joint authorship categories
50 i.e. joint first authors, joint corresponding authors and joint last authors in biomedical
51 research.
- 52 • This study provides an important benchmark on gender equity in scientific authorship for
53 other NIHR funded centres and organisations in England.
- 54 • The generalisability of the findings of this study may be limited due to differences in medical
55 specialities, research areas, institutional cultures, and levels of support to individual
56 researchers.
- 57 • Using secondary sources for determining the gender of authors may have limitations, which
58 could be avoided by seeking relevant information from original authors and institution
59 affiliation at the time of submission.

60

61 **Keywords:** Responsible Research and Innovation, Gender Equity, Scientific Authorship, National
62 Institution for Health Research, Biomedical Research Centres, Evaluation, Translational Research
63 Organisations, Translational Research, Basic Science Research.

64 INTRODUCTION

65 Promoting Responsible Research and Innovation (RRI) is a major strategy of the “Science with and
66 for Society” work programme of the European Union’s (EU) Horizon 2020 Framework Programme
67 for Research and Innovation[1]. RRI aims to build capacity and develop innovative ways to connect
68 science to society[2]. The RRI approach enables all societal members (such as researchers, citizens,
69 policymakers, businesses and third sector organisations) to work together during the research and
70 innovation process in order to better align research and innovation with the values, needs and
71 expectations of the society[1,2]. The RRI strategy includes the “keys” of public engagement, open
72 access, gender, ethics and science education, and two further “keys”: sustainability and social
73 justice, which have been added recently [3]. The idea is that by prioritising these key components of
74 RRI, it would help make science more attractive to young people and society, and raise awareness of
75 the meaning of responsible science[2].

76 We have focussed on the ‘gender’ element of the RRI because it is imperative to advance gender
77 equality within research institutions, as well as within the design and content of research and
78 innovation[1]. The issue of enhancing female participation in economic decision-making has become
79 prominent in the national, European and international spheres, with a particular focus on the
80 economic dimension of gender diversity[4]. In order to achieve a fair female participation within
81 positions of power, it is recommended that women should hold half of the total seats in board
82 rooms[5], however, a ratio between 40% and 60%, also known as a “gender balance zone”[6], is
83 considered acceptable – a threshold that is set by the European Commission[4].

84 From the perspective of gender equality in academia and scientific research, gender parity in
85 scientific authorship is an important measure of achievement. The term gender parity refers to “the
86 equal contribution of women and men to different dimensions of life” and it is operationalised as a
87 “relative equality in terms of numbers and proportions of women and men” for a particular
88 indicator”[7]. Gender (dis)parity in scientific authorship has important implications for gender equity
89 in academic advancement[8] because scientific authorship is commonly used as a measure of
90 academic productivity that is used for performance management, reward, and recognition[9,10].
91 The acceleration of women’s advancement and leadership in research is one of the stated objectives
92 of the National Institute of Health Research (NIHR) in the United Kingdom (UK) and it is imperative
93 for the RRI in the wider European research area. Yet, there is limited research concerning gender
94 equity in scientific authorship of translational research funded through NIHR biomedical research
95 centres (BRCs).

96 In the UK, women currently outnumber men in medical schools[11], however, a persistent gender
97 disparity in scientific publications remains[10,12–23]. While the proportion of women as first and
98 senior authors of original medical research has increased over the past few decades[24], women are
99 still significantly underrepresented as authors of research articles in medical journals, especially as
100 first and senior authors[14,22,23,25]. For example, in radiology the proportion of women as first
101 author increased from 8% in 1978 to 32% in 2013 and senior author increased from 7% in 1978 to
102 22% in 2013[23]. Similarly, in gastroenterology the proportion of women as first author increased
103 from 9% in 1992 to 29% in 2012, and senior author increased from 5% in 1992 to 15% in 2012[14].

104 The profile of gender equity in higher education and research has been raised by the introduction of
105 Athena SWAN-linked funding incentives by the NIHR[26–28]. While Athena SWAN awards are useful
106 markers of achievement for higher education institutions and research institutes, they alone are
107 insufficient to assess and monitor the progress of NIHR BRCs towards gender equity[29]. Currently,
108 the proportion of women and the rate of their achievements are not tracked routinely by the NIHR
109 BRCs and little is known about how much women contribute to scientific research and innovation in
110 the BRCs. It is important to inform the acceleration of women’s advancement and leadership in
111 translational research in line with the stated objectives of the NIHR within the UK and RRI within the
112 wider European research area through the collection of gender-disaggregated bibliometric data and
113 analysis of scientific authorship by gender.

114 For addressing the paucity of empirical research on women’s advancement and leadership in
115 translational research in the UK and Europe, a recent study on gender equity in Neurology suggests
116 the need for institutions to take a systematic approach to addressing gender disparities that involve
117 customised, defined metrics and transparent reporting to stakeholders[30].

118 The aim of this study was to assess the gender parity in six types of scientific authorship in
119 biomedical research.

120 **METHODS**

121 *Study design*

122 A retrospective descriptive study.

123 *Setting*

124 This study was conducted at the NIHR Oxford BRC, which is research collaboration between the
125 Oxford University Hospitals NHS Foundation Trust and the University of Oxford[31]. The aim of NIHR
126 BRCs is to support translational research and innovation to improve healthcare for patients[32].
127 During the study period (April 2012-March 2017), the NIHR Oxford BRC was awarded £96m to
128 support research across nine research themes, five cross-cutting themes, and a range of
129 underpinning platforms. The research themes included Blood, Cancer, Cardiovascular, Dementia and
130 Cerebrovascular Disease, Diabetes, Functional Neuroscience and Imaging, Infection, Translational
131 Physiology, and Vaccines. The crosscutting themes included Genomic Medicine, Immunity and
132 Inflammation, Surgical Innovation and Evaluation, Biomedical Informatics and Technology, and
133 Prevention and Population Care. The major underpinning platforms included a Biorepository,
134 Education and Training, Public Engagement, and Research Governance. It is a contractual
135 requirement to report the number of BRC supported publications published by researchers funded
136 or supported by the NIHR research funds on an annual basis. Additionally, the NIHR uses bibliometric
137 analyses to inform eligibility for NIHR funding[33,34]. This study was carried out as part of a wider
138 programme of research on the markers of achievement for assessing and monitoring gender equity
139 in translational research organisations[29].

140 **Data**

141 Data comprised translational research publications published by researchers funded or supported by
142 the NIHR Oxford BRC. The eligibility criteria for inclusion of a publication were funding or support by
143 the NIHR Oxford BRC and publication between April 2012 and March 2017. Based on these criteria,
144 2409 publications were identified. These publications were classified as: basic science studies,
145 clinical studies (both trial and non-trial studies), and other studies (comments, editorials, systematic
146 reviews, reviews, opinions, meeting reports, guidelines and protocols).

147 **Main outcome measures**

148 The main outcome measures were: (1) Gender of authors, defined as a binary variable comprising,
149 either male or female categories, (2) Six categories of scientific authorship: first author, joint first
150 authors, first corresponding author, joint corresponding authors, last author and joint last authors
151 (Figure 1). These categories are conventionally associated with the highest amount of contribution,
152 credit and prestige[10,17].

153 First author was defined as the first-named author of the publication. Publications that consisted of
154 single authors were categorised as first authors. We considered the first author to be the main
155 intellectual contributor in the publication, in terms of study design, data collection and analysis, and
156 manuscript writing. Joint first authors were defined as two or more authors who were named as
157 equal contributors and mentioned as joint first authors of the publication. The first corresponding
158 author was defined as the only author who was reported as a corresponding author in the
159 publication and his/her contact details such as an institutional address and/or an email address were
160 provided for correspondence in the publication. Joint corresponding authors were defined as two or
161 more authors who were listed or marked as corresponding authors and their contact details were
162 provided for correspondence in the publication. Last author was defined as the last-named author of
163 a publication. The last author was considered to be a group leader or principal investigator who may
164 have provided significant intellectual contribution or supervision of the research work as well as
165 acquisition of research funding[17,35]. Joint last authors were defined as two or more authors who
166 were named as equal contributors in the publication and their names were mentioned as joint last
167 authors in the publication. A major confounding factor, for which we could not control, was the
168 informal nature of the conventions for the sequence and role of authors[35]. Although conventions
169 for scientific authorship are well established in biomedical sciences[36,37], they may vary between
170 different research areas and even between different research groups within the same area.

171 **Determination of gender of authors**

172 The gender of the authors was defined as a binary variable comprising either male or female
173 categories, which were determined based on the first name of authors in all six categories of
174 authorship included in the analysis. When the first names of authors were initialled in the
175 publication or were difficult to associate with either male or female gender, further information was
176 sought through searching their institutional webpages and online social network sites such as the
177 LinkedIn and ResearchGate. We also used the Gender API (gender-api.com) when it was not possible
178 to ascertain the gender of the authors by the above-mentioned sources. In addition, we contacted
179 five authors directly via email to ascertain their gender. After completing data coding by two
180 researchers (MJM and RD), to ensure the accuracy of data coding, 10% of the data were checked

181 independently (CH). Consensus was achieved through discussion between the researchers on data
182 fields that did not match the assigning of the gender of authors and types of authorship (Figure 1).

183 ***Statistical analysis***

184 Data were analysed using frequencies including counts and percentages. Chi-square tests were used
185 for identifying statistically significant differences and associations between male and female authors
186 in various categories of authorship. The level of significance was set at $p < 0.05$. Data were analysed
187 using the IBM SPSS Statistics for Windows, Version 25.0 (Armonk, NY: IBM Corp.).

188 ***Patient and public involvement statement***

189 There was no patient or public involvement in the study design.

190 **RESULTS**

191 ***Type of research study***

192 Table 1 presents an overview of the types of research studies by year. Clinical research studies (both
193 trial and non-trial studies) comprised 39% (n=939), basic science research 27% (n=643) and a third of
194 publications (34%, n=827) included other types of research, such as systematic reviews, reviews,
195 research protocols, editorials, guidelines, opinions, comments, and meeting reports.

196 **Table 1** Number of publications by year of acceptance and types of research studies

Year (Accepted)	Types of research studies Count (%)				Total Count (%)
	Basic science	Clinical trial	Clinical study - Not a trial	Other*	
2012†	75 (27.6)	18 (6.6)	90 (33.1)	89 (32.7)	272 (100)
2013◊	151 (28.2)	27 (5.0)	183 (34.2)	174 (32.5)	535 (100)
2014◊	122 (22.2)	29 (5.3)	204 (37.2)	194 (35.3)	549 (100)
2015◊	137 (24.7)	48 (8.7)	158 (28.5)	211 (38.1)	554 (100)
2016◊	137 (31.8)	31 (7.2)	120 (27.8)	143 (33.2)	431 (100)
2017‡	21 (30.9)	5 (7.4)	26 (38.2)	16 (23.5)	68 (100)
Total	643 (26.7)	158 (6.6)	781 (32.4)	827 (34.3)	2409 (100)

197 †April-December, ◊January-December ‡January-March, *systematic reviews, reviews, research
198 protocols, editorials, guidelines, opinions, comments, and meeting reports

199 ***Authorship type and Gender***

200 Table 2 presents an overview of gender of authors by types of authorship. This highlights that male
201 authors were statistically significant more likely to be first authors (59%, χ^2 972.938, $P < 0.001$), first
202 corresponding authors (66%, χ^2 242.970, $P < 0.001$) and last authors (77%, χ^2 702.411, $P < 0.001$)
203 (Table 2). Furthermore, analyses of joint authorship categories revealed that the proportion of
204 'female only' authors was statistically significantly lower than 'male only' authors in the joint
205 corresponding authors (29%, χ^2 79.858, $P < 0.001$) and joint last authors categories (10%, χ^2 56.550,

206 P<0.001) (Table 2). However, in the joint first authors category, the proportion of ‘male and female’
 207 as joint first authors (57%, χ^2 128.467, P <0.001) was statistically significantly higher than male only
 208 and female only first authors (Table 2).

209 **Table 2.** Authorship categories and gender of authors

Authorship type Number of publications in the category	Gender of authors Count (%)			Chi-Square Test χ^2 (p)
	Male only	Female only	Male and female	
First author (n=2407)	1413 (58.7)	994 (41.3)	N/A *	72.938 (<0.001)
First corresponding author (n=2371)	1565 (66)	806 (34)	N/A	242.970 (<0.001)
Last author (n=2406)	1853 (77)	553 (23)	N/A	702.411 (<0.001)
Joint first authors (n=458)	127 (27.7)	69 (15.1)	262 (57.2)	128.467 (<0.001)
Joint corresponding authors (n=169)	107 (63.3)	49 (29)	13 (7.7)	79.858 (<0.001)
Joint last authors (n=229)	108 (47.2)	23 (10)	98 (42.8)	56.550 (<0.001)

*N/A= not applicable.

210 ***Gender of authors by type of research studies***

211 Analysis of gender of authors by types of research studies (i.e. basic science, clinical trials, non-trial
 212 clinical studies and other research) showed that the proportions of male only authors were
 213 statistically significantly higher than the proportions of female only authors in three authorship
 214 categories: first authors (χ^2 8.606 (df 3), P = 0.035), first corresponding authors (χ^2 36.955 (df 9), P <
 215 0.001) and last authors (χ^2 10.314 (df 3), P = 0.016). The analysis by type of research studies also
 216 revealed that there were no significant differences between the proportions of male only and
 217 female only authors in all three joint authorship categories: joint first authors (χ^2 5.549 (df 6), P =
 218 0.476), joint corresponding authors (χ^2 9.021 (df 6), P = 0.172) and joint last authors (χ^2 8.433 (df 6),
 219 P = 0.208).

220 ***Yearly trends in Authorship by gender***

221 Figure 2 presents the yearly trends in scientific authorship by gender. In all authorship types and
 222 across all five years of publication, the proportion of male and female authors varied (Figure 2). The
 223 analysis showed women were significantly underrepresented across all years and authorship types.
 224 Interestingly, joint first authorship indicated a higher proportion of ‘male and female’ authors
 225 compared to ‘male only’ and ‘female only’ authors (Figure 2).

226 *Association between same gender across authorship categories*

227 There was a statistically significant association between the same gender in first authorship and
228 corresponding authorship categories (χ^2 775.425 (df 3), $P < 0.001$) and the first author and joint first
229 authors (χ^2 138.849 (df 2), $P < 0.001$).

230 Furthermore, there were statistically significant associations between the same gender in the last
231 author category with the same gender of first author(s) (χ^2 33.742 (df 2), $P < 0.001$), corresponding
232 author(s) (χ^2 540.774 (df 1), $P < 0.001$) and joint last authors (χ^2 91.291 (df 2), $P < 0.001$). However,
233 there was no statistically significant association between the male and female last authors with the
234 respective gender of joint first authors (χ^2 4.29 (df 2), $P = 0.117$).

235 **DISCUSSION**

236 We retrospectively analysed the gender parity of authors in six categories of authorship of scientific
237 publications that were published over a five-year period. Our analysis shows that the number of
238 female authors were underrepresented across all six categories of authorship [10,38,39].

239 In the first author category the proportions of female authors and male authors were within the
240 40%-60% “gender balance zone”[6]. The greatest gender imbalance was observed in the last author
241 category where ‘female only’ authors comprised only 23%. Nonetheless, this proportion is higher
242 than other studies reporting similar analyses[11,16,24].

243 To the best of our knowledge, this study presents the first analysis of joint authorship in three
244 categories. Secondly, it demonstrates underrepresentation in female only authors in six categories of
245 scientific authorship[40]. Thirdly, the analysis highlights gender inequity with female
246 underrepresentation in prestigious authorship positions compared to male in biomedical research.
247 This is consistent with other fields including: epilepsy, lung cancer, dermatology, eating disorders
248 and in medicine in general[17,19,41–43].

249 This study extends understanding of gender-based trends in scientific authorship (Figure2) by
250 showing encouraging incremental changes in gender parity in authorship in a biomedical research
251 setting. Previous research examined the gender gap in authorship within the medical literature
252 reporting an upward trend for female first authors from 6% in 1970 to 29% in 2004 and female last
253 authors from 4% in 1970 to 19% 2004. However, it was limited to US based institutions[12]. A similar
254 UK based study covering the same period (i.e. 1970-2004) also showed upward trends for female
255 first authors increasing from 11% in 1970 to 37% in 2004 and female last authors from 12% in 1970
256 to 17% in 2004[24]. In addition, a recent study by Filardo et al.[16] examined the prevalence of
257 female first authorship of original research published in six high impact general medical journals
258 between February 1994 and June 2014 revealed that the adjusted probability of an article having a
259 female first authorship increased significantly from 27% in 1994 to 37% in 2014[16]. However,
260 despite the proportion of female first authors varied greatly by journal, men were generally more
261 likely to be first authors than women[16]. Compared to previous studies mentioned above, our study
262 provides evidence of higher and increasing gender equity in the first authors, last authors and other
263 four categories of scientific authorship in biomedical research (Table 2).

264 Our study identified a strong association between same gender and authorship types showing if the
265 first author of a publication was male, it was highly likely that the first corresponding author of the
266 same publication would also be male. Similarly, the likelihood of the first author being female was
267 higher, if the first corresponding author was also female[44]. Likewise, there appeared to be a
268 significant association of male and female last authors with the respective gender of first authors.
269 Previous research has highlighted males and females were more likely to be first authors on papers if
270 the last authors were of the same gender; however, these were not conducted in a translational
271 research setting[23,45–47]. There was also a strong association of male and female last authors with
272 the respective gender of corresponding authors[44].

273 However, due to the differences in gender equity between different research areas and medical
274 specialties, where a centre-specific mix of research themes is likely to influence gender equity in
275 scientific authorship, it is difficult to make direct comparisons across the literature.

276 Overall, our results build an important evidence base in biomedical research settings concerning
277 gender parity and support the findings from previous studies where analysis of scientific authorship
278 by gender has been used as an important marker of gender equity[12,24,48–50].

279 *Implications for policy and practice*

280 While NIHR BRCs routinely collect bibliometric data on publications arising from the NIHR-funded
281 research, and report to the NIHR (the funder), to the best of our knowledge, this data is not
282 routinely analysed by gender. Our study supports the feasibility of using NIHR BRCs funded or
283 supported research publications for analysing scientific authorship by gender. While retrospective
284 analysis of the gender of authors in scientific publications is labour-intensive and has limitations,
285 there is an opportunity to begin to track this prospectively. As more data becomes available, this
286 would enable longitudinal analysis of scientific authorship by gender, which could be useful for
287 tracking progress towards gender equity and related issues such as markers of achievement across
288 all NIHR BRCs.

289 In addition, since the acceleration of women’s advancement and leadership in translational research
290 is one of the stated objectives of the NIHR, investigating the extent of gender equity in scientific
291 authorship may usefully inform strategies to accelerate women’s advancement and leadership in
292 NIHR-funded research. Moreover, bibliometric analyses used by the NIHR to inform competition for
293 NIHR funding may incorporate the gender dimension into the analysis, which could provide
294 additional information on the competitiveness for NIHR funding[51,52].

295 **CONCLUSION**

296 Our results show that while first authorship is within the 40%-60% gender balance zone, a greater
297 gender disparity is prevalent in other types of scientific authorship in biomedical research. The
298 proportion of female authors is significantly lower than the proportion of male authors in all six
299 categories of authorship included in our analysis. This study also demonstrates the feasibility of
300 analysing scientific authorship by gender, which could provide useful insight about gender equity in
301 scientific publications, which may be a useful marker of achievement. Overall, our study
302 demonstrates that it is feasible to analyse the available bibliometric data on publications arising

303 from NIHR funding by gender and consider establishing processes for analysing gender equity in
304 scientific authorship over time.

305 **Contributors**

306 LDE conceived the study. RD and MJM coded the data. SGSS analysed the data. RD and SGSS drafted
307 the manuscript. PVO contributed to the conception of the study and co-wrote parts of the
308 manuscript. CRH and OC participated in data collection. VK, LRH, and AMB contributed to the
309 conception of the study, facilitated access to the publications and coordinated the study. All authors
310 read, contributed to and approved the final manuscript.

311 **Funding**

312 This study is funded by the European Union's Horizon 2020 research and innovation programme
313 award STARBIOS2 under grant agreement No. 709517 and by the National Institute for Health
314 Research (NIHR) Oxford Biomedical Research Centre, grant BRC-1215-20008 to the Oxford University
315 Hospitals NHS Foundation Trust and the University of Oxford. The views expressed are those of the
316 authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social
317 Care.

318 **Competing interests**

319 VK is Chief Operating Officer and LRH is Clinical Research Manager at the National Institute for
320 Health Research (NIHR) Biomedical Research Centre, Oxford. AMB is a senior medical science advisor
321 and co-founder of Brainomix, a company that develops electronic ASPECTS (e-ASPECTS), an
322 automated method to evaluate ASPECTS in stroke patients. MJM, LDE and PVO were funded by
323 STARBIOS2 and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre
324 (BRC). PVO is a member of the NIHR Advisory Group on Equality, Diversity, and Inclusion, a member
325 of the European Association of Science Editors Gender Policy Committee, and a member of the
326 Athena SWAN Self-Assessment Team of the Radcliffe Department of Medicine, University of Oxford.
327 The other authors declare no competing interests.

328 **Ethics**

329 The University of Oxford Clinical Trials and Research Governance Team reviewed the study and
330 deemed it exempt from full ethics review on the grounds that it falls outside of the Governance
331 Arrangements for Research Ethics Committees (GAfREC), which stipulate which research studies are
332 required to have ethics review. A wider programme of research on the activities of the NIHR Oxford
333 Biomedical Research Centre from 2017 to 2022 received ethics clearance through the University of
334 Oxford Central University Research Ethics Committee (R51801/ RE001), the Health Research
335 Authority (IRAS ID 228049) and the Oxford University Hospitals NHS Foundation Trust Management
336 (PID 12779).

337 **Acknowledgements**

338 The authors wish to thank Professor Helen McShane for reviewing the draft manuscript and making
339 comments and suggestions for improving it.

340 Patient consent for publication

341 Not required.

342 Data sharing statement

343 No additional data available.

344 REFERENCES

- 345 1 Colizzi V, Mezzana D, Ovseiko P V., *et al.* Structural transformation to attain responsible
346 BIOSciences (STARBIOS2): Protocol for a horizon 2020 funded European multicenter project
347 to promote responsible research and innovation. *J Med Internet Res* 2019;**21**.
348 doi:10.2196/11745
- 349 2 Elster D, Barendziak T, Birkholz J. Towards a Sustainable and Open Science:
350 Recommendations for Enhancing Responsible Research and Innovation in the Biosciences at
351 the University of Bremen. 2019. <http://elib.suub.uni-bremen.de/edocs/00107721-1.pdf>
- 352 3 European Commission. Indicators for promoting and monitoring Responsible Research and
353 Innovation. Report from the Expert Group on Policy Indicators for Responsible Research and
354 Innovation. 2015.
- 355 4 European Commission. DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on
356 improving the gender balance among non-executive directors of companies listed on stock
357 exchanges and related measures. Published Online First: 2012.[http://eur-](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2012:0614:FIN:en:PDF)
358 [lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2012:0614:FIN:en:PDF](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2012:0614:FIN:en:PDF)
- 359 5 European Commission. Report on Equality between Women and Men in the European Union.
360 2019;:1–78. doi:10.2838/776419
- 361 6 Kuhlmann E, Ovseiko P V., Kurmeyer C, *et al.* Closing the gender leadership gap: A multi-
362 centre cross-country comparison of women in management and leadership in academic
363 health centres in the European Union. *Hum Resour Health* 2017;**15**:1–7. doi:10.1186/s12960-
364 016-0175-y
- 365 7 European Institute for Gender Equality. Gender parity.
366 2020.<https://eige.europa.eu/thesaurus/terms/1195> (accessed 19 Feb 2020).
- 367 8 Rexrode KM. The gender gap in first authorship of research papers. *BMJ* 2016;**1130**:1–2.
368 doi:10.1136/bmj.i1130
- 369 9 Bloch C, Graverson EK, Pedersen HS. Competitive Research Grants and Their Impact on Career
370 Performance. *Minerva* 2014;**52**:77–96.
- 371 10 Bendels, M, Muller, R, Brueggmann, D, Groneberg D. Gender disparities in high-quality
372 research revealed by Nature Index journals. *PLoS One* 2018;**13**:1–21.
- 373 11 Jefferson L, Bloor K, Maynard A. Women in medicine: Historical perspectives and recent
374 trends. *Br Med Bull* 2015;**114**:5–15. doi:10.1093/bmb/ldv007
- 375 12 Jagsi, R, Guancial, E, Worobey, C, Henault, L, Chang, Y, Starr, R, Tarbell, N, Hylek E. The
376 “Gender Gap” in Authorship of Academic Medical Literature — A 35-Year Perspective. *N Engl*

- 377 *J Med* 2006;**355**:281–7.
- 378 13 Mueller CM, Gaudilliere DK, Kin C, *et al.* Gender disparities in scholarly productivity of US
379 academic surgeons. *J Surg Res* 2016;**203**:28–33. doi:10.1016/j.jss.2016.03.060
- 380 14 Long MT, Leszczynski A, Thompson KD, *et al.* Female authorship in major academic
381 gastroenterology journals: A look over 20 years. *Gastrointest Endosc* 2015;**81**:1440-1447.e3.
382 doi:10.1016/j.gie.2015.01.032
- 383 15 Fishman M, Williams WA, Goodman DM, *et al.* Gender Differences in the Authorship of
384 Original Research in Pediatric Journals, 2001-2016. *J Pediatr* 2017;**191**:244-249.e1.
385 doi:10.1016/j.jpeds.2017.08.044
- 386 16 Filardo G, Graca B, Sass DM, *et al.* Trends and comparison of female first authorship in high
387 impact medical journals: observational study (1994-2014). *BMJ* 2016;**352**:1–8.
388 doi:10.1136/bmj.i847
- 389 17 Bendels, Michael, Wanke, Eileen, Schoffel, Norman, Bauer, J, Quarcoo, David and Groneberg
390 D. Gender equality in academic research on epilepsy — a study on scientific authorships.
391 *Epilepsia* 2017;**58**:1794–802. doi:10.1111/epi.13873
- 392 18 Bendels MHK, Brüggmann D, Schöffel N, *et al.* Gendermetrics of cancer research: results
393 from a global analysis on lung cancer. *Oncotarget* 2017;;1–11.
- 394 19 Bendels MHK, Dietz MC, Brüggmann D, *et al.* Gender disparities in high-quality dermatology
395 research: a descriptive bibliometric study on scientific authorships. *BMJ Open* 2018;**8**:1–11.
396 doi:10.1136/bmjopen-2017-020089
- 397 20 Bendels MHK, Brüggmann D, Schöffel N, *et al.* Gendermetrics of cancer research: Results
398 from a global analysis on prostate cancer. *Oncotarget* 2018;**9**:19640–9.
399 doi:10.18632/oncotarget.24716
- 400 21 Sing DC, Jain D, Ouyang D. Gender trends in authorship of spine-related academic literature
401 — a 39-year perspective. *Spine J* 2017;**17**:1749–54. doi:10.1016/j.spinee.2017.06.041
- 402 22 Schisterman EF, Swanson CW, Lu Y, *et al.* The changing face of epidemiology: gender
403 disparities in citations? *Epidemiology* 2017;**28**:159–68.
404 doi:10.1097/EDE.0000000000000593.The
- 405 23 Piper CL, Scheel JR, Lee CI, *et al.* Gender trends in radiology authorship: A 35-year analysis.
406 *Am J Roentgenol* 2016;**206**:3–7. doi:10.2214/AJR.15.15116
- 407 24 Sidhu R, Rajashekhar P, Lavin VL, *et al.* The gender imbalance in academic medicine: A study
408 of female authorship in the United Kingdom. *J R Soc Med* 2009;**102**:337–42.
409 doi:10.1258/jrsm.2009.080378
- 410 25 Sing DC, Jain D, Ouyang D. Gender trends in authorship of spine-related academic literature—
411 a 39-year perspective. *Spine J* 2017;**17**:1749–54. doi:10.1016/j.spinee.2017.06.041
- 412 26 Ovseiko P V., Chapple A, Edmunds LD, *et al.* Advancing gender equality through the Athena
413 SWAN Charter for Women in Science: An exploratory study of women’s and men’s
414 perceptions. *Heal Res Policy Syst* 2017;**15**:1–13. doi:10.1186/s12961-017-0177-9
- 415 27 Ovseiko P V., Pololi LH, Edmunds LD, *et al.* Creating a more supportive and inclusive university

- 416 culture: a mixed-methods interdisciplinary comparative analysis of medical and social
417 sciences at the University of Oxford. *Interdiscip Sci Rev* 2019;**44**:166–91.
418 doi:10.1080/03080188.2019.1603880
- 419 28 Schmidt EK, Ovseiko P V, Henderson LR, *et al.* Understanding the Athena SWAN award
420 scheme for gender equality as a complex social intervention in a complex system: analysis of
421 Silver award action plans in a comparative European perspective. *bioRxiv* 2019;:555482.
422 doi:10.1101/555482
- 423 29 Ovseiko, PV, Edmunds, LD, Pololi, LH *et al.* Markers of achievement for assessing and
424 monitoring gender equity in translational research organisations: a rationale and study
425 protocol. *BMJ Open* 2016;**6**:1–11. doi:10.1136/bmjopen-2015-009022
- 426 30 Silver JK. Understanding and addressing gender equity for women in neurology. *Neurology*
427 2019;**93**:538–49. doi:10.1212/WNL.00000000000008022
- 428 31 NIHR Oxford BRC. About the NIHR Oxford Biomedical Research Centre.
429 2019.<https://oxfordbrc.nihr.ac.uk/about-us-intro/> (accessed 19 Dec 2019).
- 430 32 Greenhalgh T, Ovseiko P V., Fahy N, *et al.* Maximising value from a United Kingdom
431 Biomedical Research Centre: study protocol. *Heal Res policy Syst* 2017;**15**:70.
432 doi:10.1186/s12961-017-0237-1
- 433 33 Gunashekar S, Parks S, Calero-Medina C, *et al.* Bibliometric analysis of highly cited
434 publications of biomedical and health research in England, 2004--2013. *Bibliometric Anal*
435 *highly cited Publ Biomed Heal Res England, 2004--2013* 2016;:83.
436 doi:<https://doi.org/10.7249/RR1363>
- 437 34 Gunashekar S, Wooding S, Guthrie S. How do NIHR peer review panels use bibliometric
438 information to support their decisions? *Scientometrics* 2017;**112**:1813–35.
439 doi:10.1007/s11192-017-2417-8
- 440 35 Tschartke T, Hochberg ME, Rand TA, *et al.* Author sequence and credit for contributions in
441 multi-authored publications. *PLoS Biol* 2007;**5**:0013–4. doi:10.1371/journal.pbio.0050018
- 442 36 Wren JD, Kozak KZ, Johnson KR, *et al.* The write position. A survey of perceived contributions
443 to papers based on byline position and number of authors. *EMBO Rep* 2007;**8**:988–91.
444 doi:10.1038/sj.embor.7401095
- 445 37 ICMJE. Defining the Role of Authors and Contributors.
446 2019.[http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)
447 [the-role-of-authors-and-contributors.html](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html) (accessed 23 Dec 2019).
- 448 38 Holman L, Stuart-fox D, Hauser CE. The gender gap in science: How long until women are
449 equally represented? *PLoS Biol* 2018;**16**:1–20. doi:10.1371/journal.pbio.2004956
- 450 39 UNESCO. Women in Science. Fact Sheet. 2018.
- 451 40 Broderick NA, Casadevall A. Gender inequalities among authors who contributed equally.
452 *Elife* 2019;**8**:1–11. doi:10.7554/eLife.36399
- 453 41 Bendels MHK, Bruggmann D SN *et al.* Gendermetrics of cancer research: results from a global
454 analysis on lung cancer. *Oncotarget* 2017;:1–11.

- 455 42 Strand M, Bulik CM. Trends in female authorship in research papers on eating disorders: 20-
456 year bibliometric study. *BJPsych Open* 2018;**4**:39–46. doi:10.1192/bjo.2017.8
- 457 43 Gayet-Ageron A, Poncet A, Perneger T. Comparison of the contributions of female and male
458 authors to medical research in 2000 and 2015: A cross-sectional study. *BMJ Open* 2019;**9**:1–8.
459 doi:10.1136/bmjopen-2018-024436
- 460 44 Ouyang, D, Harrington, RA., Rodriguez F. Association Between Female Corresponding Authors
461 and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals. *Circ Am Hear*
462 *Assoc* 2019;**139**:1127–9. doi:10.1161/CIRCULATIONAHA.118.037763
- 463 45 Fox CW, Burns CS, Muncy AD, *et al.* Gender differences in patterns of authorship do not affect
464 peer review outcomes at an ecology journal. *Funct Ecol* 2016;**30**:126–39. doi:10.1111/1365-
465 2435.12587
- 466 46 Salerno PE, Páez-Vacas M, Guayasamin JM, *et al.* Male principal investigators (almost) don't
467 publish with women in ecology and zoology. *PLoS One* 2019;**14**:1–14.
468 doi:10.1371/journal.pone.0218598
- 469 47 Edwards HA, Schroeder J, Dugdale HL. Correction: Gender differences in authorships are not
470 associated with publication bias in an evolutionary journal(PLoS ONE (2019)13:8
471 (e0201725)Doi:10.1371/journal.pone.0201725). *PLoS One* 2019;**14**:1–16.
472 doi:10.1371/journal.pone.0217251
- 473 48 Bendels MHK, Müller R, Brueggmann D, *et al.* Gender disparities in high-quality research
474 revealed by nature index journals. *PLoS One* 2018;**13**:1–21.
475 doi:10.1371/journal.pone.0189136
- 476 49 Feramisco JD, Leitenberger JJ, Redfern SI, *et al.* A gender gap in the dermatology literature?
477 Cross-sectional analysis of manuscript authorship trends in dermatology journals during 3
478 decades. *J Am Dermatology* 2009;**60**:63–9. doi:10.1016/j.jaad.2008.06.044
- 479 50 Bhattacharyya N, Shapiro NL. Increased Female Authorship in Otolaryngology Over the Past
480 Three Decades. *Laryngoscope* 2000;**110**:358–61. doi:10.1097/00005537-200003000-00005
- 481 51 Van Leeuwen T, Hoorens S, Grant J. Using bibliometrics to support the procurement of NIHR
482 biomedical research centres in England. *Res Eval* 2009;**18**:71–82.
483 doi:10.3152/095820209X414178
- 484 52 Leeuwen T Van, Grant J. Bibliometric analysis of highly cited publications of health research in
485 England, 1995-2004. 2007. https://www.rand.org/pubs/working_papers/WR368.html

486 Additional files list

487 **Figure 1** Publication analysis workflow. The workflow shows the process of extracting data according
488 to gender from six types of authorship.

489 **Figure 2** Yearly trends in scientific authorship by gender (male and female), April 2012 - March 2017.
490 This plot represents the yearly variation of the proportion of male and female authors according to
491 six types of authorship between the years of publication/acceptance from 2012 to 2017.

Supplementary File 1




Figure 1 Publication analysis workflow.